» Articles » PMID: 38761335

Role of MA Modifications in Immune Evasion and Immunotherapy

Overview
Journal Med Oncol
Publisher Springer
Specialty Oncology
Date 2024 May 18
PMID 38761335
Authors
Affiliations
Soon will be listed here.
Abstract

RNA modification has garnered increasing attention in recent years due to its pivotal role in tumorigenesis and immune surveillance. N-methyladenosine (mA) modification is the most prevalent RNA modification, which can affect the expression of RNA by methylating adenylate at the sixth N position to regulate the occurrence and development of tumors. Dysregulation of mA affects the activation of cancer-promoting pathways, destroys immune cell function, maintains immunosuppressive microenvironment, and promotes tumor cell growth. In this review, we delve into the latest insights into how abnormalities in mA modification in both tumor and immune cells orchestrate immune evasion through the activation of signaling pathways. Furthermore, we explore how dysregulated mA modification in tumor cells influences immune cells, thereby regulating tumor immune evasion via interactions within the tumor microenvironment (TME). Lastly, we highlight recent discoveries regarding specific inhibitors of mA modulators and the encapsulation of mA-targeting nanomaterials for cancer therapy, discussing their potential applications in immunotherapy.

Citing Articles

METTL14-mediated m6A modification of ZFP14 inhibits clear cell renal cell carcinoma progression via promoting STAT3 ubiquitination.

Liu Z, Sun T, Zhang Z, Piao C, Kong C, Zhang X Clin Transl Med. 2025; 15(2):e70232.

PMID: 39936533 PMC: 11815563. DOI: 10.1002/ctm2.70232.


Tumor Biology Hides Novel Therapeutic Approaches to Diffuse Large B-Cell Lymphoma: A Narrative Review.

Masnikosa R, Cvetkovic Z, Piric D Int J Mol Sci. 2024; 25(21).

PMID: 39518937 PMC: 11545713. DOI: 10.3390/ijms252111384.


Tumor-related IGF2BP1-derived molecular subtypes to predict prognosis and immune microenvironment in head and neck squamous cell carcinoma.

Ding Q, Liu M, Pan Y, Wu Z, Wang J, Li Y Front Immunol. 2024; 15:1469435.

PMID: 39512352 PMC: 11540706. DOI: 10.3389/fimmu.2024.1469435.

References
1.
An Y, Duan H . The role of m6A RNA methylation in cancer metabolism. Mol Cancer. 2022; 21(1):14. PMC: 8753874. DOI: 10.1186/s12943-022-01500-4. View

2.
Wiener D, Schwartz S . The epitranscriptome beyond mA. Nat Rev Genet. 2020; 22(2):119-131. DOI: 10.1038/s41576-020-00295-8. View

3.
Dai D, Wang H, Zhu L, Jin H, Wang X . N6-methyladenosine links RNA metabolism to cancer progression. Cell Death Dis. 2018; 9(2):124. PMC: 5833385. DOI: 10.1038/s41419-017-0129-x. View

4.
Xiao S, Cao S, Huang Q, Xia L, Deng M, Yang M . The RNA N-methyladenosine modification landscape of human fetal tissues. Nat Cell Biol. 2019; 21(5):651-661. DOI: 10.1038/s41556-019-0315-4. View

5.
Zhao W, Qi X, Liu L, Ma S, Liu J, Wu J . Epigenetic Regulation of mA Modifications in Human Cancer. Mol Ther Nucleic Acids. 2019; 19:405-412. PMC: 6938965. DOI: 10.1016/j.omtn.2019.11.022. View